Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Дек. 23, 2024
Abstract
Ductal
carcinoma
in
situ
(DCIS)
is
a
noninvasive
breast
disease
that
variably
progresses
to
invasive
cancer
(IBC).
Given
the
unpredictability
of
this
progression,
most
DCIS
patients
are
aggressively
managed
similar
IBC
patients.
Undoubtedly,
treatment
paradigm
places
many
at
risk
overtreatment
and
its
significant
consequences.
Historically,
prognostic
modeling
has
included
assessment
clinicopathological
features
genomic
markers.
Although
these
provide
valuable
insights
into
tumor
biology,
they
remain
insufficient
predict
which
will
progress
IBC.
Contemporary
work
begun
focus
on
microenvironment
surrounding
ductal
cells
for
molecular
patterns
might
progression.
In
review,
extracellular
alterations
occurring
with
malignant
transformation
from
detailed.
Not
only
do
changes
collagen
abundance,
organization,
localization
mediate
transition
IBC,
but
also
discrete
post-translational
regulation
fibers
understood
promote
invasion.
Other
matrix
proteins,
such
as
metalloproteases,
decorin,
tenascin
C,
have
been
characterized
their
role
further
demonstrate
value
matrix.
Importantly,
proteins
influence
immune
fibroblasts
toward
pro-tumorigenic
phenotypes.
Thus,
progressive
play
key
invasion
promise
development.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
178, С. 117285 - 117285
Опубликована: Авг. 11, 2024
The
review
article
titled
CD39
Transforming
Cancer
Therapy
by
Modulating
Tumor
Microenvironment
published
in
June
2024
Letters
provides
a
comprehensive
overview
of
CD39's
multifaceted
roles
cancer,
particularly
its
influence
on
immunoregulation,
angiogenesis,
and
metabolic
reprogramming
within
the
tumor
microenvironment
(TME).
This
commentary
builds
that
foundation
incorporating
recent
advancements
research,
highlighting
unresolved
issues,
proposing
future
research
directions.
We
delve
into
therapeutic
potential
targeting
CD39,
addressing
clinical
translation
challenges,
exploring
integration
CD39-based
strategies
precision
oncology.
Journal of Inflammation Research,
Год журнала:
2024,
Номер
Volume 17, С. 5439 - 5452
Опубликована: Авг. 1, 2024
This
study
aims
to
investigate
the
correlation
between
a
novel
integrated
inflammatory
marker:
The
inflammation-combined
prognostic
index
(ICPI),
combining
NLR,
PLR,
and
MLR,
with
clinicopathological
characteristics
overall
survival
(OS)
of
gastric
cancer
(GC).
Nanocarrier-based
targeting
tumor-associated
macrophages
can
reprogram
pro-tumor
M2
into
anti-tumor
M1
macrophages,
offering
a
promising
approach
for
advanced
breast
cancer
treatment.
Image
created
in
BioRender.com.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
181, С. 117753 - 117753
Опубликована: Дек. 1, 2024
Chimeric
Antigen
Receptor
T-cell
(CAR-T)
therapy
has
revolutionized
the
treatment
of
hematological
malignancies.
However,
its
effectiveness
against
solid
tumors
remains
constrained
by
challenges
such
as
exhaustion,
limited
persistence,
and
off-target
effects.
These
highlight
critical
gaps
in
current
CAR-T
cell
therapeutic
strategies,
particularly
for
tumor
applications.
Circular
RNAs
(circRNAs)
represent
a
transformative
class
non-coding
RNAs,
known
their
exceptional
stability
precise
regulatory
functions,
positioning
them
promising
candidates
enhancing
next-generation
therapies.
Notably,
circRNAs
can
bridge
gap
between
preclinical
research
clinical
application
offering
innovative
solutions
to
overcome
technical
hurdles
improve
outcomes.
Despite
potential,
remain
underexplored
therapies
tumors,
presenting
significant
opportunity
innovation.
The
mechanisms
through
which
modulate
specificity
are
not
yet
fully
understood,
challenges,
achieving
efficient
targeted
circRNA
delivery,
still
need
be
addressed.
This
review
highlights
importance
integrating
into
enhance
specificity,
minimize
effects,
durability.
By
emphasizing
potential
identifying
key
gaps,
this
provides
roadmap
advancing
setting
stage
next
generation
personalized
cancer
treatments.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2024,
Номер
43(1)
Опубликована: Дек. 23, 2024
Abstract
Ductal
carcinoma
in
situ
(DCIS)
is
a
noninvasive
breast
disease
that
variably
progresses
to
invasive
cancer
(IBC).
Given
the
unpredictability
of
this
progression,
most
DCIS
patients
are
aggressively
managed
similar
IBC
patients.
Undoubtedly,
treatment
paradigm
places
many
at
risk
overtreatment
and
its
significant
consequences.
Historically,
prognostic
modeling
has
included
assessment
clinicopathological
features
genomic
markers.
Although
these
provide
valuable
insights
into
tumor
biology,
they
remain
insufficient
predict
which
will
progress
IBC.
Contemporary
work
begun
focus
on
microenvironment
surrounding
ductal
cells
for
molecular
patterns
might
progression.
In
review,
extracellular
alterations
occurring
with
malignant
transformation
from
detailed.
Not
only
do
changes
collagen
abundance,
organization,
localization
mediate
transition
IBC,
but
also
discrete
post-translational
regulation
fibers
understood
promote
invasion.
Other
matrix
proteins,
such
as
metalloproteases,
decorin,
tenascin
C,
have
been
characterized
their
role
further
demonstrate
value
matrix.
Importantly,
proteins
influence
immune
fibroblasts
toward
pro-tumorigenic
phenotypes.
Thus,
progressive
play
key
invasion
promise
development.
